RxDoctor Payments Data

Daniel Castro Pereira, MD

Nephrology · Tucson, AZNPI 1912212390

Payments from drug & device makers

$4,587in general payments, 2019–2025

Across 209 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$717
  • AstraZeneca$561
  • Fresenius USA Marketing, Inc.$501
  • OPKO Pharmaceuticals, LLC$455
  • Amgen$443
  • Otsuka America Pharmaceutical, Inc.$228
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,09689%
  • Education$49011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,587 in reported general payments places this provider in the 65th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$133,416
Medicare patients
346
Services billed
1,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone319$432,424
FarxigaDapagliflozin Propanediol320$423,277
JardianceEmpagliflozin129$165,440
VelphoroSucroferric Oxyhydroxide48$134,947
VeltassaPatiromer Calcium Sorbitex20$45,579
JanuviaSitagliptin Phosphate13$20,537
InvokanaCanagliflozin13$19,954
Cinacalcet Hcl16$14,896
RybelsusSemaglutide12$11,888
Sevelamer Carbonate58$11,600
Calcium Acetate80$9,823
Calcitriol399$8,619
Bumetanide219$7,866
DapagliflozinDapagliflozin Propanediol12$6,155
Chlorthalidone169$4,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$717$432,424319 claims
AstraZenecaFarxiga$561$423,277320 claims
Fresenius USA Marketing, Inc.Velphoro$501$134,94748 claims
Johnson & JohnsonInvokana$30$19,95413 claims
Novo NordiskRybelsus$114$11,88812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 259 nephrology providers in Arizona.

Other nephrology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →